Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY: Home Monitoring in Neovascular AMD
NCT01863199Phase 4Completed
- Sponsor
- Retinal Consultants of Arizona
- Start
- May 2013
- Primary completion
- Nov 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Retinal Consultants of Arizona. Started May 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01863199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863199.